United Therapeutics to develop, sell Arena Pharma's hypertension treatment
(Reuters) – United Therapeutics Corp on Thursday signed a deal potentially worth up to $ 1.2 billion for the rights to develop and sell Arena Pharmaceuticals Inc’s pulmonary arterial hypertension treatment(PAH). The two companies said the deal for Arena’s late-stage experimental treatment, ralinepag, includes milestone payments of up to $ 400 million based on certain… Read More »